Uy Ear
Stock Analyst at Mizuho
(4.16)
# 471
Out of 5,182 analysts
83
Total ratings
48.08%
Success rate
18.6%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Maintains: Outperform | $10 → $19 | $7.24 | +162.43% | 3 | Mar 20, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $26 → $31 | $21.07 | +47.13% | 10 | Mar 13, 2026 | |
| QURE uniQure | Upgrades: Outperform | $12 → $35 | $18.05 | +93.91% | 8 | Mar 11, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $37 → $35 | $23.32 | +50.09% | 16 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Outperform | $29 → $35 | $22.67 | +54.39% | 16 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $128.12 | +36.59% | 11 | Dec 12, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $5.27 | +260.53% | 4 | Dec 2, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $34.14 | +31.81% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $29.04 | +92.84% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $27.20 | +212.50% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $6.80 | +488.24% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $227.79 | -82.44% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.86 | +249.65% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.66 | +80.72% | 2 | Mar 1, 2023 |
Relmada Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $10 → $19
Current: $7.24
Upside: +162.43%
Sarepta Therapeutics
Mar 13, 2026
Maintains: Outperform
Price Target: $26 → $31
Current: $21.07
Upside: +47.13%
uniQure
Mar 11, 2026
Upgrades: Outperform
Price Target: $12 → $35
Current: $18.05
Upside: +93.91%
Arcutis Biotherapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $37 → $35
Current: $23.32
Upside: +50.09%
ACADIA Pharmaceuticals
Feb 23, 2026
Upgrades: Outperform
Price Target: $29 → $35
Current: $22.67
Upside: +54.39%
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $128.12
Upside: +36.59%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $5.27
Upside: +260.53%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $34.14
Upside: +31.81%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $29.04
Upside: +92.84%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $27.20
Upside: +212.50%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $6.80
Upside: +488.24%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $227.79
Upside: -82.44%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.86
Upside: +249.65%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.66
Upside: +80.72%